A5075835334- Gastric Cancer Management and Outcomes
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Brain Metastases and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Research Studies
- Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Neuroendocrine Tumor Research Advances
- Renal cell carcinoma treatment
- Gastrointestinal Tumor Research and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Pancreatic and Hepatic Oncology Research
- Fibroblast Growth Factor Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Advanced Breast Cancer Therapies
- MRI in cancer diagnosis
- Cancer survivorship and care
- Glioma Diagnosis and Treatment
- Nutrition and Health in Aging
- Sarcoma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- COVID-19 and healthcare impacts
- Patient-Provider Communication in Healthcare
- Frailty in Older Adults
Bezmiâlem Vakıf Üniversitesi
2016-2025
Pfizer (United Kingdom)
2020
Gaziantep University
2002-2013
Inonu University
2000-2001
Turgut Özal Tıp Merkezi
2001
Humboldt State University
1998
Charité - Universitätsmedizin Berlin
1998
There is an urgent need for first-line treatment options patients with human epidermal growth factor receptor 2 (HER2)-negative, locally advanced unresectable or metastatic gastric gastroesophageal junction (mG/GEJ) adenocarcinoma. Claudin-18 isoform (CLDN18.2) expressed in normal cells and maintained malignant G/GEJ adenocarcinoma cells. GLOW (closed enrollment), a global, double-blind, phase 3 study, examined zolbetuximab, monoclonal antibody that targets CLDN18.2, plus capecitabine...
Abstract Background We report the final results of randomized phase 2 FIGHT trial that evaluated bemarituzumab, a humanized monoclonal antibody selective for fibroblast growth factor receptor 2b (FGFR2b), plus mFOLFOX6 in patients with FGFR2b-positive (2 + /3 membranous staining by immunohistochemistry), HER-2–negative gastric or gastroesophageal junction cancer (GC). Methods Patients received bemarituzumab (15 mg/kg) placebo once every weeks an additional (7.5 dose on cycle 1 day 8. All...
160 Background: Bemarituzumab (bema), a first-in-class humanized IgG1 monoclonal antibody, selectively binds to FGFR2b, inhibits ligand binding and mediates antibody-dependent cell-mediated cytotoxicity. A phase 1 study of bema monotherapy in solid tumors had no dose-limiting toxicities confirmed objective response rate (ORR) 18% patients (pts) with refractory FGFR2b+ gastric cancer (GC). Methods: The FIGHT (NCT03343301) is global, randomized, double-blind, placebo-controlled 2 trial. Pts...
405736 Background: There is an unmet need for novel targeted therapies that improve outcomes pts with HER2− LA unresectable or mG/GEJ adenocarcinoma. CLDN18.2 expressed in normal gastric mucosa cells and retained most G/GEJ adenocarcinomas. In the phase 3 SPOTLIGHT study, zolbetuximab, a CLDN18.2-targeted chimeric monoclonal antibody, significantly prolonged PFS OS CLDN18.2+/HER2− adenocarcinoma when combined mFOLFOX6. GLOW (NCT03653507) global, double-blind study comparing zolbetuximab PBO...
To compare the seropositivity rate of cancer patients with noncancer controls after inactive SARS-CoV-2 vaccination and evaluate factors affecting seropositivity.
Geriatric syndromes may be more common in older cancer patients than those without cancer. can cause poor clinical outcomes. The Eastern Cooperative Oncology Group Performance Status (ECOG-PS) is often used as a clinically reported functional status score oncology practice.
4010 Background: Bema is a first-in-class humanized IgG1 monoclonal antibody selective for fibroblast growth factor receptor 2b (FGFR2b). Results from the FIGHT study showed an improvement in progression-free survival (PFS), overall (OS), and response rate with addition of bema to mFOLFOX6 FGFR2b+, non HER2+ GC. This report provides updated analyses patient (pt) subgroups, additional data on ocular adverse events (AEs), median OS result bema+mFOLFOX6 combination. Methods: Pts were treated...
Central nervous system (CNS) metastases can be seen at a rate of 30% in advanced stages for patients with non-small cell lung cancer (NSCLC). Growing evidence indicates the predictive roles driver gene mutations development brain (BM) recent years, meaning that oncogene-driven NSCLC have high incidence BM diagnosis. Today, 3rd generation targeted drugs intracranial efficacy, which cross blood-brain barrier, made positive contribution to survival these an increased propensity BM. It is...
Background: In recent years, reducing adjuvant treatment period from 6 months to 3 in low‐risk stage colon cancer has shown no decline efficiency and fewer adverse effects, particularly neuropathy. Aim: We examined the efficacy side effects of 3‐ 6‐month chemotherapy regimens patients. Methods: Twelve oncology centers retrospectively scanned operated, low‐risk, (T1‐3, N1) Capecitabine oxaliplatin (CAPOX) were given all 3‐month patients, while patients received FOLFOX orCAPOX. Two groups...
Background and Objectives: Conversion surgery for liver metastatic colorectal cancer (mCRC) has been associated with prolonged survival. This study aimed to evaluate the efficacy safety of integrating biological therapies fluorouracil-based induction chemotherapy in patients isolated mCRC who subsequently underwent curative resection both primary tumor metastases. Materials Methods: multicenter, retrospective study, conducted by Turkish Oncology Group (TOG), included 116 from 11 tertiary...
Malignant and nonmalignant serosal fluids have been found to be associated with high serum levels of CA 125, suggesting that the presence fluid in cavities may stimulate its release. In this study, we investigated relationship between 125 pleural patients chronic heart failure (CHF). We performed a clinical study 36 CHF without fluid. Patients were divided into two groups based on cavity. Group 1 included 18 (6 females, 12 males) 2 consisted (7 11 The control group 30 healthy volunteers (12...
The prognosis of breast cancer patients with brain metastasis is poor. It was aimed to define the clinicopathological features metastases and determine risk factors survival outcomes associated metastasis. This a single-center, retrospective, cross-sectional study. A total number 127 diagnosed who developed between January 2011 March 2021 were retrospectively analyzed. data these according 4 biological subtypes evaluated (luminal A, luminal B, HER-2 overexpressing, triple-negative). median...
Abstract Background In the EMPOWER‐Lung 1 trial ( ClinicalTrials.gov , NCT03088540), cemiplimab conferred longer survival than platinum‐doublet chemotherapy for advanced non–small cell lung cancer (NSCLC) with programmed death‐ligand (PD‐L1) ≥50%. Patient‐reported outcomes were evaluated among participants. Methods Adults NSCLC and Eastern Cooperative Oncology Group performance status 0 to randomly assigned 350 mg every 3 weeks or chemotherapy. At baseline day of each treatment cycle,...
Aim: To assess the anxiety levels of breast cancer patients during COVID-19 pandemic. Materials & methods: A total 298 completed State-Trait Anxiety Inventory (STAI-S and STAI-T) Visual Analogue Scale for (VAS) VAS in (VAS-CoV). Results: 144 were high category STAI-S, 202 STAI-T. STAI-T score was significantly metastatic group (p = 0.017). VAS-CoV hormonotherapy higher than no-treatment 0.023). There a positive correlation between (r 0.708, p < 0.001), STAI-S scores 0.402, 0.001; r 0.185,...
<i>Objective:</i> To report an unusual paraneoplastic syndrome, amyotrophic lateral sclerosis, associated with renal cell carcinoma. <i>Case Presentation and Intervention:</i> A 59-year-old man presented muscle weakness fasciculations in the upper extremities. Neurological examination showed that arose spontaneously limbs. Electrodiagnostic studies revealed active neurogenic disorder. The patient was diagnosed a motor neuron disease mimicking sclerosis. Urine analysis...